BOULDER, CO - Aug 22, 2025 (UTC) - KromaTiD, a pioneering force in next-generation genomic structural analysis, announced the successful close of its Series C funding round, raising a total of $8 million and surpassing its targeted capital goals. The most recent tranche of the round contributed $3.8 million. Led by BroadOak Capital Partners with participation from existing and new strategic investors, this investment will accelerate KromaTiD’s growth in providing essential genomic integrity analysis for gene and cell therapy developers.
Funding Details
KromaTiD’s $8 million Series C funding round, announced on August 20, 2025, represents a key milestone in expanding its proprietary platforms for genomic structural analysis. The round was led by BroadOak Capital Partners, with participation from both existing and new strategic investors, highlighting strong support for KromaTiD’s role in the gene and cell therapy industry.
“We are thrilled to have achieved our funding goal, which is a testament to the confidence our investors have in our vision and the unique capabilities of our technology,” said Jim Chomas, CEO of KromaTiD. “This investment enables us to scale faster, innovate further, and continue delivering the genomic insights that help bring life-changing therapies to patients.”
“KromaTiD has built a differentiated platform that provides accurate, high-resolution analysis of genomic integrity, one of the most pressing needs in the rapidly expanding gene and cell therapy industry,” said Bill Snider, Partner at BroadOak Capital Partners. “We are proud to continue our partnership as they enter their next phase of growth.”
Strategic Goals and Use of Funds
KromaTiD will utilize the $8 million Series C funding to advance its strategic priorities in the genomic analysis sector. The key initiatives include:
- Platform Expansion: Enhance proprietary platforms for detecting chromosomal structural rearrangements to support gene and cell therapy development.
- Operational Scaling: Increase laboratory automation and throughput to meet growing global demand.
- Strategic Partnerships: Advance collaborations with pharmaceutical and academic leaders in cell and gene therapy.
- Commercial Acceleration: Expand market presence and customer-facing teams over the next 12-18 months.
- Talent Acquisition: Invest in hiring across scientific, operational, and customer support roles to drive innovation and service excellence.
These efforts aim to solidify KromaTiD’s leadership in providing high-resolution genomic insights for therapeutic innovation.
Historical Funding and Growth
KromaTiD’s funding history demonstrates its evolution in the genomic analysis field. The table below summarizes its known funding rounds:
| Round | Date | Amount | Lead Investor | Key Notes |
|---|---|---|---|---|
| SBIR Grant | August 2020 | Undisclosed | National Human Genome Research Institute | Supported development of genomic analysis technologies. |
| Growth Capital | 2021 | $2M | BroadOak Capital Partners | Accelerated commercialization and product development. |
| Series C | August 2025 | $8M | BroadOak Capital Partners | Focused on platform expansion, operational scaling, and partnerships. |
Founded in 2007 and headquartered in Longmont, Colorado, KromaTiD has grown into a leader in cytogenetic precision for genomic innovation. The company has developed proprietary technologies for single-cell chromosomal analysis, supporting gene and cell therapy from discovery to regulatory approval. With increasing adoption in the biopharma sector, KromaTiD has expanded its services to include GLP and GMP testing, positioning it for continued growth in the expanding gene therapy market.
KromaTiD’s Technology
KromaTiD specializes in next-generation genomic structural analysis, combining proprietary imaging and bioinformatics to detect chromosomal structural rearrangements with high resolution. Key offerings include:
- KROMASURE™ Platform: A fit-for-purpose solution for cell and gene therapy research, providing single-cell analysis and high-confidence insights into genomic integrity.
- KROMASURE™ Screen: High-sensitivity karyotyping for profiling chromosome mutations.
- KROMASURE™ KBand: Genomic integrity G-Banding with detailed structural variant analysis.
- KROMASURE™ InSite: Directional Genomic Hybridization (dGH) for edit site integrity and transgene mapping.
- KROMASURE™ PinPoint: High-resolution assay using custom probes for targeted genomic analysis.
The platform supports orthogonal testing to sequencing, donor cell testing, IND submissions, and transgene mapping, enabling precise genomic insights for gene editing and therapy development.
Industry Impact and Challenges
KromaTiD’s technologies address critical needs in the gene and cell therapy industry, where accurate genomic integrity analysis is essential for ensuring safe and effective treatments. By providing high-resolution detection of structural variants and chromosomal rearrangements, KromaTiD supports therapeutic developers in navigating regulatory requirements and accelerating innovation. The company’s solutions have been adopted by leading biopharma and academic partners, contributing to advancements in life-changing therapies.
The genomic analysis sector faces challenges such as increasing complexity in gene editing, regulatory hurdles for IND filings, and the need for scalable, high-throughput testing. KromaTiD must continue to innovate in automation and precision to maintain its competitive edge in a rapidly evolving market.
Market Context and Industry Trends
The gene and cell therapy market is projected to reach $25 billion by 2027, driven by advancements in CRISPR and other editing technologies. Key trends include:
- Genomic Integrity Focus: Growing demand for high-resolution analysis to detect structural variants and ensure therapy safety.
- Regulatory Compliance: Increasing emphasis on orthogonal testing for IND submissions and GMP batch release.
- Automation and Scalability: Need for high-throughput platforms to support expanding clinical pipelines.
- Strategic Partnerships: Collaboration between tech providers and biopharma for integrated solutions.
- Innovation in Gene Editing: Rise of precise tools for transgene mapping and edit site verification.
KromaTiD’s proprietary platforms align with these trends, positioning the company to capitalize on the expanding need for genomic analysis in therapy development.
Stakeholder Perspectives
KromaTiD’s leadership highlights the funding’s role in scaling operations and innovating further to meet industry demands. Investors emphasize the company’s differentiated platform and its potential to address key challenges in gene and cell therapy.
Stakeholder Insights
Stakeholders note KromaTiD’s unique capabilities in providing accurate genomic insights, which are crucial for advancing safe therapies. The focus on high-resolution analysis and strategic growth positions the company for long-term success in a competitive landscape.
About KromaTiD
Founded in 2007 and headquartered in Longmont, Colorado, KromaTiD delivers next-generation genomic structural analysis solutions for gene and cell therapy developers. The company’s KROMASURE™ platform enables precise detection of chromosomal rearrangements, supporting innovation from discovery through regulatory approval. Led by CEO Jim Chomas, KromaTiD’s mission is to provide cytogenetic precision for genomic integrity, ensuring better and safer treatments for patients.
Future Outlook
With the $8 million Series C funding, KromaTiD is well-positioned for accelerated growth in 2025 and beyond. The company plans to expand its platforms, enhance automation, and strengthen partnerships over the next 12-18 months. By investing in talent and operations, KromaTiD aims to solidify its leadership in genomic structural analysis and support the rapid expansion of gene and cell therapies.
Media Contact
For more information, visit kromatid.com or contact Amanda Ladas at aladas@kromatid.com.
Source : KromaTiD
